Drug Trial Radar · NCT05499013
Study to Assess SLN124 in Patients With Polycythemia Vera
Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
69
Actual
Start
Jan 26, 2023
Primary completion
Sep 2026
Study completion Mar 2030
Sponsor
- Lead sponsor
- Silence Therapeutics plcIndustry
- Sponsor type
- Industry
- First posted
- Aug 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.
Conditions
- Polycythemia Vera
Interventions
SLN124Drug
SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).
PlaceboDrug
sodium chloride, solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Incidence of treatment-emergent adverse events (AEs)Time frame: Day 239
- Phase 1: Assessment of the number of phlebotomies at intervalsTime frame: 6 months prior to dosing to Day 239
- Phase 2: Proportion of patients who achieve response between week 18 and week 36 (placebo controlled double blind phase)Time frame: 18 to 36 weeks
Locations
28 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Hammond, Louisiana
Research Site
Buffalo, New York
Research Site
New York, New York
Research Site
Columbus, Ohio
Research Site
Huntsville, Texas
Research Site
Benowa, Australia
Research Site
Hobart, Australia
Research Site
Kurralta Park, Australia
Research Site 2
Melbourne, Australia
Research Site
Melbourne, Australia
Linear Clinical Research
Nedlands, Australia
Research Site
Richmond, Australia
Research Site 2
Plovdiv, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Toronto, Canada
Research Site
Freiburg im Breisgau, Germany
Research Site
Hanover, Germany
Research Site
Alessandria, Italy
Research Site
Meldola, Italy
Research Site
Johor Bahru, Malaysia
Research Site
Kuala Terengganu, Malaysia
Research Site
Kuantan, Malaysia
Research Site
Kuching, Malaysia
Research Site
Gdansk, Poland
Research Site
Katowice, Poland
Research Site
Lublin, Poland
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.